Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators
Johan Vijgen,Gianluca Botto,John Camm,Carl Johan Höijer,Werner Jung,Jean-Yves Le Heuzey,Andrzej Lubiński,Tone M. Norekvål,Maurizio Santomauro,Martin J. Schalij,Jean-Paul Schmid,Panos Vardas +11 more
Reads0
Chats0
TLDR
The EHRA task force on ICD and driving was formed to reassess the risk of driving for ICD patients based on the literature available and the recommendations are summarized in the following table.Abstract:
Patients with an implantable cardioverter defibrillator (ICD) have an ongoing risk of sudden incapacitation that might cause harm to others while driving a car. Driving restrictions vary across different countries in Europe. The most recent recommendations for driving of ICD patients in Europe were published in 1997 and focused mainly on patients implanted for secondary prevention. In recent years there has been a vast increase in the number of patients with an ICD and in the percentage of patients implanted for primary prevention. The EHRA task force on ICD and driving was formed to reassess the risk of driving for ICD patients based on the literature available. The recommendations are summarized in the following table and are further explained in the document. [table: see text] Driving restrictions are perceived as difficult for patients and their families, and have an immediate consequence for their lifestyle. To increase the adherence to the driving restrictions, adequate discharge of education and follow-up of patients and family are pivotal. The task force members hope this document may serve as an instrument for European and national regulatory authorities to formulate uniform driving regulations.read more
Citations
More filters
Journal ArticleDOI
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)
Perry M. Elliott,Aris Anastasakis,Michael A. Borger,Martin Borggrefe,Franco Cecchi,Philippe Charron,Albert Hagège,Antoine Lafont,Giuseppe Limongelli,Heiko Mahrholdt,William J. McKenna,Jens Mogensen,Petros Nihoyannopoulos,Stefano Nistri,Petronella G. Pieper,Burkert Pieske,Claudio Rapezzi,Frans H. Rutten,Christoph Tillmanns,Hugh Watkins +19 more
TL;DR: The objective of this study was to establish a baseline level of confidence that the once-in-a-lifetime implantation trial—Reduce Inappropriate Therapy protocol can be trusted to provide safe and effective treatment for cardiac arrhythmia and stroke-like episodes.
Journal ArticleDOI
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)
TL;DR: In this article, the authors proposed AMIOdarone versus implantable cardioverter-defibrillator (ICD-DV) for the treatment of atrial fibrillation.
Journal ArticleDOI
2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
Silvia G. Priori,Carina Blomström-Lundqvist,Andrea Mazzanti,Nico A. Blom,Martin Borggrefe,John Camm,Perry M. Elliott,Donna Fitzsimons,Robert Hatala,Gerhard Hindricks,Paulus Kirchhof,Keld Kjeldsen,Karl Heinz Kuck,Antonio Hernández-Madrid,Nikolaos Nikolaou,Tone M. Norekvål,Christian Spaulding,Dirk J. van Veldhuisen +17 more
TL;DR: This poster presents a probabilistic procedure to determine the best method for selecting a single drug to treat atrial fibrillation-like symptoms in patients with a history of atrialfibrillation.
Journal ArticleDOI
Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC)
TL;DR: Guidelines and Expert Consensus Documents summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategies for a typical patient, suffering from a given condition, taking into account the impact on outcome, as well as the risk/benefit ratio of particular diagnostic or therapeutic means.
Journal ArticleDOI
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).
Silvia G. Priori,Carina Blomström-Lundqvist,Andrea Mazzanti,Nico A. Blom,Martin Borggrefe,John Camm,Perry M. Elliott,Donna Fitzsimons,Robert Hatala,Gerhard Hindricks,Paulus Kirchhof,Keld Kjeldsen,Karl-Heinz Kuck,Antonio Hernández-Madrid,Nikolaos Nikolaou,Tone M. Norekvål,Christian Spaulding,Dirk J. van Veldhuisen +17 more
TL;DR: In this article, the authors proposed AMIOdarone versus implantable cardioverter-defibrillator (ICD-DV) for the treatment of atrial fibrillation.
References
More filters
Journal ArticleDOI
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Arthur J. Moss,Wojciech Zareba,W. Jackson Hall,Helmut U. Klein,David J. Wilber,David S. Cannom,James P. Daubert,Steven L. Higgins,Mary W. Brown,Mark L. Andrews +9 more
TL;DR: In patients with a prior myocardial infarction and advanced left ventricular dysfunction, prophylactic implantation of a defibrillator improves survival and should be considered as a recommended therapy.
Journal ArticleDOI
Amiodarone or an implantable cardioverter-defibrillator for congestive Heart failure
Gust H. Bardy,Kerry L. Lee,Daniel B. Mark,Jeanne E. Poole,Douglas L. Packer,Robin Boineau,Michael J. Domanski,Charles Troutman,Jill Anderson,Steven McNulty,Nancy E. Clapp-Channing,Linda Davidson-Ray,Elizabeth S. Fraulo,Daniel P. Fishbein,Richard M. Luceri,John Ip +15 more
TL;DR: In patients with NYHA class II or III CHF and LVEF of 35 percent or less, amiodarone has no favorable effect on survival, whereas single-lead, shock-only ICD therapy reduces overall mortality by 23 percent.
Journal ArticleDOI
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Michael R. Bristow,Leslie A. Saxon,John P. Boehmer,Steven K. Krueger,David A. Kass,Teresa De Marco,Peter E. Carson,Lorenzo DiCarlo,David L. DeMets,Bill G. White,Dale W DeVries,Arthur M. Feldman +11 more
TL;DR: In this paper, the authors tested the hypothesis that prophylactic cardiac-resynchronization therapy in the form of biventricular stimulation with a pacemaker with or without a defibrillator would reduce the risk of death and hospitalization among patients with advanced chronic heart failure and intraventricular conduction delays.
Journal ArticleDOI
Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
Arthur J. Moss,W. Jackson Hall,David S. Cannom,James P. Daubert,Steven L. Higgins,Helmut U. Klein,Joseph H. Levine,Sanjeev Saksena,Albert L. Waldo,David J. Wilber,Mary W. Brown,Moonseong Heo +11 more
TL;DR: In this article, the authors studied whether prophylactic therapy with an implanted cardioverter-defibrillator, as compared with conventional medical therapy, would improve survival in this high-risk group of patients.
Journal ArticleDOI
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
TL;DR: Among survivors of ventricular fibrillation or sustained ventricular tachycardia causing severe symptoms, the implantable cardioverter-defibrillator is superior to antiarrhythmic drugs for increasing overall survival.